The Division of Neurology I (DNI) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of neurological diseases and conditions, such as Alzheimer’s disease, stroke, Parkinson’s disease, Huntington’s disease, epilepsy, migraine headaches, muscular dystrophy, amyotrophic lateral sclerosis, multiple sclerosis, dementia, and narcolepsy.
- Director: Eric Bastings, M.D (Acting)
- Deputy Director for Safety: Alice Hughes, M.D.
- Safety Regulatory Project Manager: Christine Phipps, Pharm.D.
- Regulatory Operations Chief, Project Management Staff: Jacqueline Ware, Pharm.D.
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4346
Phone: (301) 796-2250
Fax: (301) 796-9842